Profile
YCBD ZTS HLN TAK TEVA NBIX
Company Name cbdMD, Inc. Zoetis Inc. Haleon plc Takeda Pharmaceutical Company Limited Teva Pharmaceutical Industries Limited Neurocrine Biosciences, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $3.11M $76.41B $42.03B $41.37B $24.60B $14.37B
Employees 0.05K 14.10K 25.41K 49.28K 37.00K 1.70K
CEO Mr. T. Ronan Kennedy Ms. Kristin C. Peck Mr. Brian James McNamara Mr. Christophe Weber Mr. Richard D. Francis Mr. Kyle W. Gano Ph.D.
Ratings
YCBD ZTS HLN TAK TEVA NBIX
Quant Rating Score 1 3 3 3 1 4
Quant Rating Strong Sell Neutral Neutral Neutral Strong Sell Buy
Trading
YCBD ZTS HLN TAK TEVA NBIX
Last Close $0.5606 $169.37 $9.19 $13.05 $21.68 $141.92
High 52 $1.1 $199.94 $10.69 $15.08 $22.77 $153.15
Low 52 $0.34 $145.54 $8.01 $12.6 $10.99 $111.62
Price vs. 52 Week High -49.04 % -15.29 % -14.03 % -13.46 % -4.79 % -7.33 %
Price vs. 52 Week Low 64.88 % 16.37 % 14.73 % 3.57 % 97.27 % 27.15 %
Total Return
YCBD ZTS HLN TAK TEVA NBIX
1 Month Return 27.7 % -0.83 % -7.27 % -2.32 % 3.83 % 3.83 %
3 Month Return 27.41 % -11.35 % -8.78 % -8.45 % 20.71 % 19.82 %
6 Month Return -13.09 % -6.97 % 3.03 % -4.74 % 32.36 % -1.89 %
9 Month Return -39.07 % 11.47 % 13.32 % -0.76 % 64.49 % 6.52 %
YTD Return 49.49 % 3.95 % -3.67 % -1.44 % -1.63 % 3.97 %
1 Year Return -24.65 % -11.28 % 8.37 % -12.15 % 96.55 % 3.5 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
YCBD ZTS HLN TAK TEVA NBIX
Dividend Yield Percentage (TTM) - 1.02 % 1.66 % 4.75 % - -
Dividend Paid and Capex Coverage Ration (TTM) -1.24 % 2.1 % - 1.34 % 3.8 % 13.12 %
Dividend Per Share (TTM) - 1.73 % 0.06 % 192 % - -
Payout Ratio (TTM) - 31.44 % - 101.62 % - -
Growth
YCBD ZTS HLN TAK TEVA NBIX
Asset Growth -34.66 % -4.28 % -2.18 % 8.25 % -1.2 % 37.27 %
Gross Profit Growth -19.91 % 3.7 % 5.84 % 1.76 % 9.65 % 26.06 %
Revenue Growth -19.35 % 5.74 % 4.09 % 5.87 % 6.17 % 26.76 %
Revenue 3 Year -87.6 % 31.98 % 13.9 % 33.13 % -6.91 % 71.93 %
Revenue 5 Year -92.41 % 53.64 % 32.87 % 103.83 % -23.33 % 308.36 %
Revenue 10 Year - 103.1 % 32.87 % 152.69 % -40.82 % 44100.16 %
EBIT Growth 64.23 % 6.27 % 9.37 % -56.36 % -84.52 % 0.76 %
Net Income Growth 83.87 % 10.88 % -1.04 % -54.56 % 76.24 % 61.62 %
Net Income 3 Yeari Growth Per Share 95.52 % 47.55 % -8.67 % -61.74 % 86.29 % -41.58 %
Net Income 5 Yeari Growth Per Share 99.25 % 71.94 % 59.66 % 32.36 % 76.28 % 1054.95 %
Net Income 10 Yeari Growth Per Share - 404.24 % 59.66 % 35.42 % -133.42 % 470.4 %
Operating Income Growth 64.23 % 6.27 % 9.37 % -56.36 % -84.52 % 0.76 %
Operating Cash Flow Growth (CFG) 91.8 % 23.06 % 1.79 % -26.69 % -13.96 % 14.88 %
Operating 3 Year CFG 99.29 % 14.12 % 48.8 % -29.25 % 10.09 % 62.6 %
Operating 5 Year CFG 99.79 % 37.69 % 166.36 % 118.64 % -48.98 % 275.6 %
Operating 10 Year CFG - 274.61 % 166.36 % 384.17 % -67.94 % 1000.37 %
EPS Growth 114.49 % 12.64 % - -54.92 % 76.42 % 59.01 %
EPS Diluted Growth 114.49 % 12.92 % - -54.86 % 76.42 % 58.33 %
Book Value Per Share -89.81 % 15.25 % 1.35 % 13.54 % -7.25 % 28.15 %
Share Holder 3 Year Equity Growth Per Share 438.89 % 36.7 % -36.6 % 40.38 % -26.74 % 88.86 %
Share Holder 5 Year Equity Growth Per Share 381.26 % 139.55 % -39.41 % 41.33 % -53.44 % 353.33 %
Share Holder 10 Year Equity Growth Per Share - 476.36 % -39.41 % 195.14 % -74.76 % 1167.34 %
Dividend Per Share Growth -100 % 15.15 % -85.58 % 1.95 % - -
Dividend 3 Year Growth Per Share -100 % 87.76 % -83.69 % 1.19 % - -
Dividend 5 Year Growth Per Share - 198.29 % -66.42 % 101.42 % -100 % -
Dividend 10 Year Growth Per Share - 665.58 % -66.42 % 102.58 % -100 % -
Debt Growth 34384.11 % -16.5 % -9.43 % 10.53 % -6.53 % 62.95 %
Free Cash Flow Growth 86.02 % 22.25 % 1.67 % -31.4 % -19.19 % 11.99 %
Updated On 30 Sep 2024 31 Dec 2023 31 Dec 2023 31 Mar 2024 31 Dec 2023 31 Dec 2023
Profitability
YCBD ZTS HLN TAK TEVA NBIX
Gross Profit Margin TTM 60.12 % 68.87 % 60.68 % 55.23 % 49.84 % 98 %
Return on Assets TTM -44.42 % 16.93 % 3.26 % 1.99 % -2.38 % 10.92 %
Return on Equity TTM -124.4 % 47.99 % 6.54 % 4.04 % -14.6 % 15.68 %
Return on Capital Employed TTM -165.42 % 26.36 % 7.22 % 4.18 % 1.6 % 18.91 %
Net Income Per EBT TTM 127.04 % 79.65 % 65.38 % 108.74 % 176.38 % 73.98 %
EBT Per Ebit TTM 113.93 % 91.46 % 82.95 % 52.35 % -125.67 % 88.81 %
EBIT Per Revenue TTM -16.67 % 36.45 % 17.82 % 11.21 % 2.67 % 26.19 %
Cash Flow To Debt Ratio TTM -28.29 % 43.6 % - 16.58 % 9.63 % 189.5 %
Receivables Turnover TTM 19.8 6.49 5.27 6.3 4.84 4.66
Payables Turnover TTM 5.04 7.05 1.23 4.92 3.55 0.47
Inventory Turnover TTM 3.29 1.18 3.03 1.69 2.12 0.98
Fixed Asset Turnover TTM 3231.98 % 259.93 % 604.62 % 240.84 % 277.85 % 664.93 %
Asset Turnover TTM 184.12 % 63.75 % 33.71 % 31.2 % 40.16 % 63.45 %
Operating Cash Flow Per Share TTM -0.08 6.5 - 528.88 1.64 4.71
Free Cash Flow Per Share TTM -0.15 5.1 - 321.24 1.21 4.35
Cash Per Share TTM 56.87 % 378.45 % 5.72 % 57241.03 % 292.94 % 1214.64 %
Operating Cash Flow Sales Ratio TTM -1.84 % 32.18 % - 18.42 % 11.07 % 21.24 %
Free Cash Flow Operating Cash Flow Ratio TTM 180.72 % 78.37 % - 60.74 % 73.71 % 92.38 %
Cash Flow Coverage Ratios TTM -28.29 % 43.6 % - 16.58 % 9.63 % 189.5 %
Price To Free Cash Flows Ratio TTM -4.78 33.11 - 12.59 18.05 32.65
Price To Operating Cash Flows Ratio TTM -6.73 26.05 - 7.64 13.29 30.12
Price Cash Flow Ratio TTM -6.73 26.05 - 7.64 13.29 30.12
Income Statement (TTM)
YCBD ZTS HLN TAK TEVA NBIX
Revenue $0.02B $8.54B $11.3B $4263.76B $15.85B $1.89B
Gross Profit $0.01B $5.83B $6.96B $2832.26B $7.65B $1.85B
Gross Profit Ratio 61.57% 68.28% 61.59% 66.43% 48.25% 97.9%
EBITDA $-0B $3.69B $2.35B $874.6B $1.57B $0.36B
Net Income $-0B $2.34B $1.05B $144.07B $-0.56B $0.25B
EPS Diluted 1.93 5.07 0.11 91.16 -0.5 2.47
Balance Sheet (MRQ)
YCBD ZTS HLN TAK TEVA NBIX
Long Term Debt $0B $6.75B $8.8B $5029.93B $18.48B $0.26B
Total Liabilities $0.01B $9.3B $17.33B $7834.79B $35.35B $1.02B
Total Equity $1.96B $4.99B $16.73B $7274.01B $8.13B $2.23B
Total Investments $0B $0.02B $0.07B $445.7B $0.01B $1.63B
Total Debt $1.27B $6.76B $9.46B $4843.75B $20.15B $0.43B
Total Assets $0.01B $14.29B $34.06B $15108.79B $43.48B $3.25B
Cash Flow Statement (TTM)
YCBD ZTS HLN TAK TEVA NBIX
Net Income $-0B $2.34B $1.11B $144.07B $-0.62B $0.25B
Inventory $0B $-0.36B $-0.13B $-115.74B $0B $0.01B
Dividends Paid $0B $-0.69B $-0.39B $-287.19B $0B $0B
Operating Cash Flow $-0B $2.35B $2.1B $716.34B $1.37B $0.39B
Capital Expenditure $-0B $-0.73B $-0.34B $-480.73B $-0.53B $-0.03B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 3.85
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 1.61
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 13.26
ALVOW Alvotech 3.16
AMPH Amphastar Pharmaceuticals, Inc. 35.7
AMRX Amneal Pharmaceuticals, Inc. 8.26
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 58.46
AQST Aquestive Therapeutics, Inc. 3.095
ASRT Assertio Holdings, Inc. 0.8278
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 7.75
AYTU Aytu BioPharma, Inc. 1.762
ETFs With Exposure to YCBD
Ticker ETF Name Weight Percentage Price
VTI Vanguard Total Stock Market Index Fund 0 296.27
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 131.48
VXF Vanguard Extended Market Index Fund 0 197.42
THCX The Cannabis ETF 1.83 16.5963
POTX Global X Cannabis ETF 0.02 5.15
TOKE Cambria Cannabis ETF 1.56 4.9
CNBS Amplify Growth Opportunities ETF 0 1.84
YOLO AdvisorShares Pure Cannabis ETF 0.02 2.33
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 148.82
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 148.83
JKK iShares Morningstar Small-Cap Growth ETF 0 307.42
JKL iShares Morningstar Small-Cap Value ETF 0 172.726
VEMPX Vanguard Extended Market Index InstlPlus 0 367.25
Unlock